SuperworthEditas Medicine EPS EDIT
Diluted earnings per share by quarter and over the last twelve months, from 2015.
- Last 12 months, to Jun 30, 2026
- −$0.75
- Latest quarter, Q2 FY26
- −$0.15
- Fiscal year 2025
- −$1.89
Editas Medicine's earnings per share was −$0.75 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.15.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.89 | n/a |
| FY2024 | −$2.88 | n/a |
| FY2023 | −$2.05 | n/a |
| FY2022 | −$3.21 | n/a |
| FY2021 | −$2.85 | n/a |
| FY2020 | −$2.00 | n/a |
| FY2019 | −$2.67 | n/a |
| FY2018 | −$2.33 | n/a |
| FY2017 | −$2.99 | n/a |
| FY2016 | −$3.03 | n/a |
| FY2015 | −$30.82 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.15 | n/a | −$0.75 | |
| Q1 FY26 | −$0.26 | n/a | −$1.23 | |
| Q4 FY25 | −$0.06 | n/a | −$1.89 | |
| Q3 FY25 | −$0.28 | n/a | −$2.38 | |
| Q2 FY25 | −$0.63 | n/a | −$2.85 | |
| Q1 FY25 | −$0.92 | n/a | −$3.04 | |
| Q4 FY24 | −$0.55 | n/a | −$2.88 | |
| Q3 FY24 | −$0.75 | n/a | −$2.56 | |
| Q2 FY24 | −$0.82 | n/a | −$2.36 | |
| Q1 FY24 | −$0.76 | n/a | −$2.10 | |
| Q4 FY23 | −$0.23 | n/a | −$2.05 | |
| Q3 FY23 | −$0.55 | n/a | −$2.70 |
Against its peers
Companies in Biotechnology nearest Editas Medicine's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| EDITEditas Medicine | −$0.75 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Editas Medicine
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.